Shaping the Future of Immunotherapy in NSCLC

In the final episode, Shaping the Future of Immunotherapy in NSCLC, the panelists explore the following critical questions:

• Which additional data would you like to see with immunotherapies used in NSCLC?
• What is the relevance of the EMPOWER-Lung 3 for patients and payors?
• How do you see the future management of NSCLC evolving with immunotherapies and do you see a potential role for extended dosing?

Led by Dr. Chul Kim, Dr. Brian Henick examines immunotherapies in NSCLC, in which clinicians are increasingly looking for long-term survival data, real-world effectiveness, and head-to-head comparisons between agents to guide optimal treatment selection. Additional safety and tolerability data, particularly in diverse patient populations, would help refine risk–benefit assessments. The EMPOWER-Lung 3 trial provides critical insights into cemiplimab plus chemotherapy, demonstrating meaningful improvements in overall survival and supporting its value for both patients and payors. For payors, this data can inform coverage decisions and highlight cost-effectiveness relative to standard therapies. Looking ahead, NSCLC management is likely to become more personalized, integrating biomarker-driven approaches and combination strategies to maximize patient outcomes. Extended dosing schedules may also play a role, offering greater convenience, potentially reducing toxicity, and supporting adherence without compromising efficacy.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Between the Lines series on NSCLC. Please subscribe to our newsletter for information on upcoming video series.